|
|
I'd like to invest in Haim Bio. Where do I start? |
|
|
|
Common stocks of Haim Bio are issued as uniform stocks and are currently traded on the over-the-counter market. If you are interested in investing in the company, please acquire common stocks from the over-the-counter market. |
|
|
|
When do I get listed in the shareholder list after acquiring Haim Bio stocks? |
|
|
|
The company stocks are uniform stocks that are readily traded on the over-the-counter market. Therefore, you are considered to be listed in the shareholder list once your purchased stocks are deposited in the security account. |
|
|
|
What are the future plans to increase capital at Haim Bio? |
|
|
|
We do not currently have plans to increase capital, but once we have future plans to increase capital, the plans will be published on the company website after the decision of the BOD. In case of capital increase by allocation to stockholder, the decision will be published on the company website and notified to individual shareholder. |
|
|
|
When does Haim Bio plan to be enlisted? |
|
|
|
The timing is unknown, but the company will be enlisted by considering the progress in nonclinical and clinical experiments. If we see successful results from phase 1 or 2 clinical test according to plan, we expect to list in 2020. |
|
|
|
What is the anti-cancer drug technology that's being developed by Haim Bio? |
|
|
|
This technology induces the destruction of cancer cells by lowering the metabolic energy of cancer cells by using NYH817G and NYH100P as active ingredients. |
|
|
|
Is it true that metabolic anti-cancer drug by Haim Bio is the first being developed in Korea and overseas? |
|
|
|
The metabolic anti-cancer drug being developed by Haim Bio by using NYH817G and NYH100P as the active ingredients is being developed first in the whole world by selectively interrupting the energy metabolism of cancer cells. |
|
|
|
What are the development schedules of anti-cancer drug at Haim Bio? |
|
|
|
We are currently under the nonclinical test, which is expected to be completed in late 2018 or early 2019 if it goes in plan. Based on the results, we plan to file for the clinical test for Investigational New Drugs (IND) in 2019. |
|
|
|
The company owns patented technology related with polyphosphate. What is this technology about? |
|
|
|
The patent related with polyphosphate has been transferred in the Q1 2016. It has a wide range of use from pharmaceutical products to health supplements and beauty products, and we plan to develop related products in the future. |
|
|
|